EFFICIENCY OF CANEPHRON H IN THE COMPLEX TREATMENT OF SUBCLINICAL SIGNS OF VASCULAR DAMAGE IN PATIENTS WITH ARTERIAL HYPERTENSION AND CHRONIC PYELONEPHRITIS
DOI:
https://doi.org/10.11603/1811-2471.2019.v0.i1.10056Keywords:
arterial hypertension, chronic pyelonephritis, subclinical signs of vascular damage, Canephron HAbstract
The purpose of the research is to study the effectiveness of Canephron H in the complex treatment of subclinical signs of vascular damage in patients with arterial hypertension (HPT) with chronic pyelonephritis (CPN).
Material and Methods. The study included 40 patients with HPT and CPN, who were divided into two groups depending on the treatment. Group I consisted of 20 patients receiving baseline therapy – a fixed low-dose combination of perindopril arginine 2 mg, indapamide 0.625 mg, amlodipine 5 mg and atorvastatin 10 mg; group ІІ – 20 patients receiving on the background of basic therapy Canephron H 2 tablets per os 3 times a day during a month. Repeated course of the proposed treatment scheme was performed after 6 months.
The evaluation of the effectiveness of the proposed treatment was determined by the dynamics of the parameters of the elastic properties of the vessels (velocity of the pulse wave – VPW, cardio-ankle vascular index – CAVI, aortic stiffness index – ASI, thickness intima – media complex – TIMC) and endothelial dysfunction (endothelin-1 – ET-1, endothelium dependent vasodilatation – EDVD, endothelium independent vasodilatation – EIVD).
Results. During treatment, there were decrease in VPW (p<0.001) and CAVI (p<0.001) in patients of two groups, however, more pronounced changes at the end of treatment were in patients of group II. During the year, ASI (p<0.001) decreased from treatment in all patients equally, but a significant decrease in TIMC was noted in patients of group ІІ – 6 months (p<0.01) versus 12 months (p<0.001) in patients of group I. Canephron N in the complex treatment contributed to a more pronounced decrease in the content of ET-1 (p<0.001) in comparison with baseline therapy, and there was a significant improvement in endothelium function with a more dynamic increase in EDVD (p<0.001) and EIVD (p<0.001).
Conclusions. 1. Canephron H in combination with combined low-dose antihypertensive therapy promotes regression of subclinical signs of vascular damage in patients with comorbid pathology. 2. The use of Canephron H in patients with hypertension and chronic pyelonephritis is expedient, safe and effective.
References
Tomiyama, H., Ishizu, T., & Kohro, T. (2018). Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. Int. J. Cardiol., 253, 161-166.
Amosova, K.M., Shyshkina, N.V., & Rudenko, Yu.V. (2017). Pokaznyky arterialnoi zhorstkosti, khvyl vidobrazhennia i shlunochkovo-arterialnoi vzaiemodiii v patsiientiv z arterialnoiu hipertenziieiu i sertsevoiu nedostatnistiu zi zberezhenoiu ta znyzhenoiu fraktsiieiu vykydu livoho shlunochka [Indices of arterial stiffness, reflection and ventricular-arterial interaction in patients with arterial hypertension and heart failure with preserved and reduced left ventricular ejection fraction]. Ukrainskyi kardiolohichnyi zhurnal – Ukrainian Cardiology Journal, 5, 13-17 [in Ukrainian].
Martyniuk L.P., Butvyn S.M., & Mylnikova, T.O. (2018). Efektyvnist likuvannia retsydyvuiuchoho piielonefrytu z vykorystanniam Kanefronu N u khvorykh zi znyzhenoiu funktsiieiu nyrok [Effectiveness of treatment of recurrent pyelonephritis using Canephron H in patients with reduced renal function]. Zhurnal “Nyrky” – Journal “Kidneys”, 7 (3) [in Ukrainian].
Smiian, S.I., & Franchuk, M.V. (2015). Efektyvnist Kanefronu N v kompleksnomu likuvanni subklinichnoi podahrychnoi nefropatii [The effectiveness of Canephron H in the complex treatment of subclinical gouty nephropathy]. Hazeta “Zdorovia Ukrainy” – Newspaper “Health of Ukraine”, October, 16-17 [in Ukrainian].
Martyniuk, L.P., Martyniuk, L.P., & Martyniuk, O.S. (2014). Efektyvnist zastosuvannia Kanefrona N u kompleksnomu likuvanni khvorykh z diabetychnoiu nefropatiieiu na tli tsukrovoho diabetu 2-ho typu [Effectiveness of Canephron H application in the complex treatment of patients with diabetic nephropathy on the background of type 2 diabetes mellitus]. Semeynaya meditsyna – Family Medicine, 3 (53), 69-76 [in Ukrainian].
Chistik, T. (2015). Vliyaniye kanefrona N na techeniye diabeticheskoy nefropatii u patsiyentov s sakharnym diabetom 2-go tipa [Effect of Canephron H on the course of diabetic nephropathy in patients with type 2 diabetes mellitus]. Novyny medytsyny ta farmatsii – News of Medicine and Pharmacy, 2 (526), 11 [in Russian].
